SCHEMBL3740375

SCHEMBL3740375

COc1cc(Br)ccc1Cl.[MgH2]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 3/20 0.45
POLB P06746 2/20 0.45
RECQL P46063 1/20 0.45
DYRK1A Q13627 1/20 0.42
NPC1 O15118 1/20 0.42
ACLY P53396 1/20 0.41
TSHR P16473 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
USP2 O75604 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263669 0.98 MAPT (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL858370 0.80 ALDH1A1 (0.51) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL30424732 0.80 ALDH1A1 (0.51) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1256865 0.79 CA2 (0.54) MAPTALDH1A1POLBTSHRKDM4E
SCHEMBL29419589 0.77 CA2 (0.56) MAPTALDH1A1POLBTSHRKDM4E
SCHEMBL20509 0.77 CA2 (0.56) MAPTALDH1A1POLBTSHRKDM4E
SCHEMBL15969085 0.76 HPGD (0.42) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL30214873 0.76 HPGD (0.42) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1129397 0.76 MAPT (0.48) MAPTALDH1A1GAAPOLBRECQL
SCHEMBL2878953 0.75 CSNK2A1 (0.43) MAPTALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114867-B1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-7829563-B2 Aminoamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2010-11-09 US disclosed
EP-2114867-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. Hoffmann-Roche AG (CH) 2009-11-11 EP disclosed
WO-2008107335-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-12 WO disclosed
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-09-11 US disclosed
US-7026515-B2 Optically active amine derivatives and preparation process therefor MITSUI CHEMICALS, INC. (JP) 2006-04-11 US disclosed
US-6875866-B2 Process for synthesis of D1 receptor antagonists SCHERING CORPORATION (US) 2005-04-05 US disclosed
US-20040030144-A1 Optically active amine derivative and method of synthesis MITSUI CHEMICALS, INC. (JP) 2004-02-12 US disclosed
US-20030199690-A1 Process for synthesis of D1 receptor antagonists SCHERING CORPORATION 2003-10-23 US disclosed
EP-1340743-A1 OPTICALLY ACTIVE AMINE DERIVATIVE AND METHOD OF SYNTHESIS Mitsui Chemicals, Inc. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040030144-A1 Optically active amine derivative and method of synthesis ALDH7A1, AADAT, KMO MAPT 3116/4885ALDH1A1 84/4885MEN1 1560/4885
US-20030199690-A1 Process for synthesis of D1 receptor antagonists OPRL1, AVPR1A, AVPR1B MAPT 4019/4885ALDH1A1 359/4885MEN1 1755/4885
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HCRTR1, HCRTR2, HRH3 MAPT 2958/4885ALDH1A1 1610/4885MEN1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.